The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City: A New Threat to Our Antibiotic Armamentarium
Abstract
BACKGROUND: Carbapenem antibiotics are used to treat serious infections caused by extended-spectrum beta-lactamase-carrying pathogens. Carbapenem resistance has been unusual in isolates of Klebsiella pneumoniae. In this study, the prevalence and molecular epidemiologic characteristics of carbapenem-resistant K pneumoniae are analyzed, and the experience involving 2 hospital outbreaks is described. METHODS: A citywide surveillance study was conducted in hospitals in Brooklyn. An observational study involving subsequent outbreaks at 2 hospitals was undertaken. Isolates were genetically fingerprinted by ribotyping and were examined for the presence of KPC-type carbapenem-hydrolyzing beta-lactamases. RESULTS: Of 602 isolates of K pneumoniae collected during the citywide surveillance study, 45% had extended-spectrum beta-lactamases. Of the extended-spectrum beta-lactamase-producing isolates, 3.3% carried the carbapenem-hydrolyzing beta-lactamase KPC-2. Several isolates were reported by the clinical microbiology laboratories as being susceptible to imipenem. Although all the isolates were resistant using agar diffusion methods, minimal inhibitory concentrations of imipenem were substantially lower for several isolates using standard broth microdilution tests and were highly dependent on the inoculum used. Two hospitals experienced the rapid spread of carbapenem-resistant isolates involving 58 patients. Overall 14-day mortality for bacteremic patients was 47%. Most isolates belonged to a single ribotype. CONCLUSIONS: Carbapenem-resistant K pneumoniae isolates are rapidly emerging in New York City. The spread of a strain that possesses a carbapenem-hydrolyzing beta-lactamase has occurred in regional hospitals. Because these isolates are resistant to virtually all commonly used antibiotics, control of their spread is crucial. However, automated systems used for susceptibility testing may not accurately identify all these isolates, which will severely hamper control efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Yigit, H., Queenan, A. M., Anderson, G. J., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., Alberti, S., Bush, K., & Tenover, F. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1151-1161.2001 · Cited by 1,639 · cited 1×
“5 Resistant D (1) 32 32 32 8 1 Resistant E (1) 32 32 32 16 16 Resistant E (2) 32 32 32 8 2 Susceptible E (3) 32 32 32 16 8 Resistant F (1) 32 32 32 16 16 NA G (1) 32 32 32 4 2 Susceptible H (1) 32 32 32 16 4 Susceptible I (1) 32 32 32 16 16 Resistant A (1) 32 32 32 16 16 Resistant A (2) 32 32 32 16 16 Resistant A (3)…”
Nosocomial infections in medical intensive care units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00020 · Cited by 1,565
Gold, H. S., & Moellering, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351907 · Cited by 1,070
Jacoby, G. A., & Munoz-Price, L. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041359 · Cited by 787
Paterson, D. L., Ko, W.-C., Gottberg, A. V., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-1-200401060-00008 · Cited by 631
Bradford, P. A., Bratu, S., Urban, C., Visalli, M., Mariano, N., Landman, D., Rahal, J. J., Brooks, S., Cebular, S., & Quale, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421495 · Cited by 485
Self-citationBradford, P. A., Urban, C., Mariano, N., Projan, S. J., Rahal, J. J., & Bush, K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.563 · Cited by 450
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
“The KPC carbapenemases in particular have recently been associated with major outbreaks of multidrug-resistant Gram-negative infections in hospitals, including those in the New York City metropolitan area (10, 12, 70) and in Israel (32), with their spread now becoming worldwide (43, 63, 68).”
BackgroundThe real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,579
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir202 · Cited by 1,033
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Woodford, N., Turton, J. F., & Livermore, D. M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00268.x · Cited by 885
Resistance in Gram-Negative Bacteria: Enterobacteriaceae
Paterson, D. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.013 · Cited by 874
Tacconelli, E., Cataldo, M. A., Dancer, S. J., De Angelis, G., Falcone, M., Frank, U., Kahlmeter, G., Pan, A., Petrosillo, N., Rodríguez-Baño, J., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12427 · Cited by 864
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 733
Xu, L., Sun, X., & Ma, X. (2017) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-017-0191-3 · Cited by 661
Hospital Epidemiology and Infection Control in Acute-Care Settings
Sydnor, E. R. M., & Perl, T. M. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-10 · Cited by 652
“The first carbapenemase-producing Klebsiella species were reported in the late 1990s (360); however, these organisms did not gain notoriety until outbreaks of KPC-producing Klebsiella species were reported around the world (34, 36, 180, 306, 332).”
BackgroundTreatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Self-citationQureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Resistance in gram-negative bacteria: Enterobacteriaceae
Paterson, D. L. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.238 · Cited by 535
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
Livermore, D. M., & Woodford, N. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.07.008 · Cited by 510
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
Schwaber, M. J., Klarfeld-Lidji, S., Navon-Venezia, S., Schwartz, D., Leavitt, A., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-07 · Cited by 483
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
Schwaber, M. J., Lev, B., Israeli, A., Solter, E., Smollan, G., Rubinovitch, B., Shalit, I., Carmeli, Y., & the Israel Carbapenem-Resistant Enterobacteriaceae Working Group (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir025 · Cited by 453
Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Prekates, A., Themeli-Digalaki, K., & Tsakris, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03514.x · Cited by 438
The rapid spread of carbapenem-resistant Enterobacteriaceae
Potter, R. F., D’Souza, A. W., & Dantas, G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.002 · Cited by 403
Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae
Bush, K. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.006 · Cited by 398
Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
Ben-David, D., Kordevani, R., Keller, N., Tal, I., Marzel, A., Gal-Mor, O., Maor, Y., & Rahav, G. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03478.x · Cited by 353
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.009 · Cited by 352
Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues
Miriagou, V., Cornaglia, G., Edelstein, M., Galani, I., Giske, C. G., Gniadkowski, M., Malamou-Lada, E., Martinez-Martinez, L., Navarro, F., Nordmann, P., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03116.x · Cited by 350
Carbapenemases: Molecular Diversity and Clinical Consequences
Poirel, L., Pitout, J. D., & Nordmann, P. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.501 · Cited by 309
Emergence of Klebsiella pneumoniae Carbapenemase-Producing Bacteria
Arnold, R. S., Thom, K. A., Sharma, S., Phillips, M., Kristie Johnson, J., & Morgan, D. J. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e3181fd7d5a · Cited by 307
Bratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., & Landman, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki175 · Cited by 307
Self-citationRisk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae
Gasink, L. B., Edelstein, P. H., Lautenbach, E., Synnestvedt, M., & Fishman, N. O. (2009) · Infection Control & Hospital Epidemiology · doi:10.1086/648451 · Cited by 306
Carbapenem-Resistant Enterobacteriaceae: A Potential Threat
(2008) · JAMA · doi:10.1001/jama.2008.896 · Cited by 298
The continuing challenge of ESBLs
PEREZ, F., ENDIMIANI, A., HUJER, K., & BONOMO, R. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.08.003 · Cited by 298
Carbapenemase-producing Enterobacteriaceae: Overview of a major public health challenge
Nordmann, P. (2014) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2013.11.007 · Cited by 279
Rodriguez-Bano, J., Navarro, M. D., Romero, L., Muniain, M. A., Cueto, M. D., Rios, M. J., Hernandez, J. R., & Pascual, A. (2006) · Clinical Infectious Diseases · doi:10.1086/508877 · Cited by 279
Walther-Rasmussen, J., & Høiby, N. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm226 · Cited by 271
Kanj, S. S., & Kanafani, Z. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0674 · Cited by 269
Carbapenem-Resistant Enterobacteriaceae
Iovleva, A., & Doi, Y. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.01.005 · Cited by 263
Carbapenemase-Producing Enterobacteriaceae
Paterson, D., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0035-1544208 · Cited by 257
Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J., & Carmeli, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00299-07 · Cited by 256
Carmeli, Y., Akova, M., Cornaglia, G., Daikos, G. L., Garau, J., Harbarth, S., Rossolini, G. M., Souli, M., & Giamarellou, H. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03115.x · Cited by 253
Holden, V. I., Wright, M. S., Houle, S., Collingwood, A., Dozois, C. M., Adams, M. D., & Bachman, M. A. (2018) · mSphere · doi:10.1128/msphere.00125-18 · Cited by 42
Metadata
- Authors
- Bratu, S., Landman, D., Haag, R., Recco, R., Eramo, A., Alam, M., & Quale, J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2005-06-27
- Volume
- 165
- Issue
- 12
- Pages
- 1430
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1990965169
- Cited by
- 573
- References
- 21
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.